All Eyes On Amjevita, Amgen’s Humira Biosimilar And Sole 2023 Product Launch

Dual Pricing Strategy Addresses Unique US Payer Priorities

The company launched Amjevita on the same day it announced fourth quarter 2022 earnings and provided 2023 guidance, upping the high-profile nature of the first-to-market US Humira biosimilar.  

Close-up Of man using Binoculars
Many are watching the Amjevita launch to see what it portends for uptake of other Humira biosimilars • Source: Shutterstock

Amgen, Inc. has set the bar for Humira (adalimumab) biosimilar launches in the US with the 31 January launch of Amjevita, the first adalimumab biosimilar to enter the market, but with two different prices – at a 55% and 5% discount to AbbVie Inc.’s pricing for the originator product.

The strategy gives payers two options from which to start reimbursement negotiations, highlighting one of the key challenges biosimilar manufacturers...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Drug Pricing

More from Scrip